InvestorsHub Logo
Followers 13
Posts 865
Boards Moderated 0
Alias Born 02/17/2017

Re: Bobbyinvest post# 33575

Monday, 01/14/2019 6:47:58 PM

Monday, January 14, 2019 6:47:58 PM

Post# of 232961
There’s also that whole IP issue... since Pestell’s (rather, CytoDyn’s) patent would specifically - by name - protect against the use of maraviroc in any cancer indication related to the inhibition of cancer metastasis. Even if a company wanted to sell the toxicity to cancer patients, which sounds like a pretty bad idea, they couldn’t do it. Vicriviroc is also specifically named, so even if Pfizer wanted to try to rehab that one... too bad.

So yeah, not much competition out there for the big ticket indications. The whole situation blows my mind if I think too hard about it.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News